Cyclacel Pharmaceuti (CYCC)

$0.28 +0.05 (21.62%)
Market Cap 47.73M
Revenue (ttm) 40,000.00
Net Income (ttm) -11.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28,025.00%
Debt to Equity Ratio 0.00
Volume 3,723,318
Avg Vol 263,450
Day's Range N/A - N/A
Shares Out 207.34M
Stochastic %K 48%
Beta 0.15
Analysts Strong Buy
Price Target $1.00

Latest News on CYCC

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Apr 2, 2025, 4:05 PM EDT - 23 days ago

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Mar 24, 2025, 7:30 AM EDT - 4 weeks ago

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

CYCCP

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Feb 27, 2025, 1:38 PM EST - 2 months ago

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

CYCCP

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Jan 3, 2025, 9:01 AM EST - 4 months ago

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

CYCCP

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Dec 5, 2024, 4:05 PM EST - 5 months ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

CYCCP

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 14, 2024, 4:15 PM EST - 5 months ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 13, 2024, 12:22 PM EST - 5 months ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Nov 12, 2024, 4:45 PM EST - 5 months ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Oct 24, 2024, 9:15 AM EDT - 6 months ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

CYCCP

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 23, 2024, 9:15 AM EDT - 6 months ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 9:15 AM EDT - 7 months ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Sep 25, 2024, 9:15 AM EDT - 7 months ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

CYCCP

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:15 AM EDT - 8 months ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

CYCCP

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Sep 3, 2024, 9:15 AM EDT - 8 months ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:18 PM EDT - 9 months ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Aug 7, 2024, 9:15 AM EDT - 9 months ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

CYCCP

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Jun 26, 2024, 9:15 AM EDT - 10 months ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

CYCCP

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Jun 4, 2024, 8:00 AM EDT - 11 months ago

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:08 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

May 8, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

CYCCP

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

May 2, 2024, 4:30 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

CYCCP

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CYCCP

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Apr 1, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 6:09 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

CYCCP

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 7, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

CYCCP

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Mar 6, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

CYCCP

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Feb 20, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

CYCCP

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Jan 30, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

CYCCP

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jan 8, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

CYCCP

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Jan 2, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

CYCCP

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Dec 22, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

CYCCP

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Dec 18, 2023, 9:00 AM EST - 1 year ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

CYCCP

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Dec 12, 2023, 4:05 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

CYCCP

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Nov 30, 2023, 9:15 AM EST - 1 year ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

CYCCP

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Nov 28, 2023, 5:15 PM EST - 1 year ago

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:32 PM EST - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

Nov 7, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

CYCCP

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

Aug 3, 2023, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

CYCCP

Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript

May 11, 2023, 7:59 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

May 4, 2023, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

CYCCP

Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit

May 3, 2023, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit

CYCCP

Cyclacel Pharmaceuticals to Participate in March Investor Conferences

Mar 7, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Participate in March Investor Conferences

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Call Transcript

Mar 6, 2023, 9:04 PM EST - 2 years ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update

Mar 6, 2023, 4:05 PM EST - 2 years ago

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update

CYCCP

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results

CYCCP

Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference

Jan 30, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference

CYCCP

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

Jan 5, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

CYCCP